In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients
Maria Vassilakopoulou(Yale University), Amanda Psyrri(National and Kapodistrian University of Athens), Dimitrios Pectasides(National and Kapodistrian University of Athens), George Pentheroudakis(Hellenic Cooperative Oncology Group), Taiwo A. Togun(Yale University), David L. Rimm(Yale University), George Fountzilas(Hellenic Cooperative Oncology Group), Vassiliki Kotoula(Aristotle University of Thessaloniki), Veronique Neumeister(Yale University), Urania Dafni(Frontier Science Foundation-Hellas), Huan Cheng(Yale University), Mattheos Bobos(Aristotle University of Thessaloniki), Dimosthenis Skarlos(Metropolitan Hospital), Jennifer Bordeaux(Lineage Cell Therapeutics (United States))
Cited by 27
Related Papers
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
|JAMA Oncology|2015|834
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2014|760